跳至主要内容
临床试验/NCT00610350
NCT00610350已完成4 期

Levosimendan Pre-Treatment in Patients Undergoing Coronary Artery Bypass Graft Surgery: a Double-Blind, Single Center, Prospective, Randomized, Placebo-Controlled Trial

University of Roma La Sapienza1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2005年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
100
试验地点
1
主要终点
Length of ICU stay

研究概览

简要总结

The aim of this study is to investigate whether pharmacological pre-treatment with levosimendan reduces intensive care unit (ICU) length of stay in patients undergoing elective myocardial revascularization under cardiopulmonary bypass.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age ≥18 years
  • intention to perform first-time multi-vessel CABG

排除标准

  • unstable angina
  • valvular disease
  • diabetes mellitus treated with sulphonylurea drugs
  • renal failure
  • severe hepatic disease
  • severe chronic obstructive pulmonary disease
  • a history of prior CABG surgery
  • recent myocardial infarction (MI) within the previous month

研究组 & 干预措施

L

Experimental

干预措施: levosimendan (Drug)

P

Experimental

干预措施: Placebo (Drug)

结局指标

主要结局

Length of ICU stay

时间窗: two weeks

次要结局

  • Length of hospital stay(3 weeks)
  • Tracheal intubation time(one week)
  • Inotropic support over the first 7 days(one week)

研究者

发起方
University of Roma La Sapienza
申办方类型
Other

研究点 (1)

Loading locations...

相似试验